Gene: CNOT6L

246175
CCR4b
CCR4-NOT transcription complex subunit 6 like
protein-coding
4q21.1
Ensembl:ENSG00000138767 Vega:OTTHUMG00000160832 UniprotKB:Q96LI5
NC_000004.12
SNP Mapped
2   ANCO-SNPs
AD
0   
1.221e-1 (AD)  2.421e-1 (ND)   (Frontal_Cortex)
1.239e-1 (AD)  1.865e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6828302chr4:77818978 (GRCh38.p7)G>A / G>Calcohol dependenceSNV(Single Nucleotide Variation)
rs2102116chr4:77751014 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PKN20.856
SMCHD10.838
LATS10.825
SMAD40.821
SLAIN20.821
UBR50.817
SREK10.815
MIER30.814
CNOT60.812
KIAA15510.812

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.496
OR4F29-0.485
HES5-0.287
CRH-0.258
NKX2-8-0.221
LCN1-0.217
SPRR2A-0.207
BTBD17-0.2
LYPD8-0.195
ZSCAN1-0.192

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of CNOT6L mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of CNOT6L mRNA26690555
C006632arsenic trioxidearsenic trioxide results in increased expression of CNOT6L mRNA20458559
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CNOT6L mRNA19770486
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of CNOT6L mRNA"19150397
C006780bisphenol Abisphenol A results in decreased expression of CNOT6L mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of CNOT6L mRNA26079696
D016572CyclosporineCyclosporine results in decreased expression of CNOT6L mRNA25562108
D003703DemecolcineDemecolcine results in decreased expression of CNOT6L mRNA23649840
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of CNOT6L mRNA]27941970
C041517dibenzo(a,l)pyrene"dibenzo(a,l)pyrene results in increased expression of CNOT6L mRNA"25908611
D0151279,10-Dimethyl-1,2-benzanthracene"9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CNOT6L mRNA"22485181
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT6L mRNA22079256
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of CNOT6L mRNA29097150
D005557FormaldehydeFormaldehyde results in decreased expression of CNOT6L mRNA23649840
D005839GentamicinsGentamicins results in increased expression of CNOT6L mRNA22061828
C544151jinfukangjinfukang results in decreased expression of CNOT6L mRNA27392435
D008345ManganeseManganese results in increased expression of CNOT6L mRNA17175027
C025340manganese chloridemanganese chloride results in increased expression of CNOT6L mRNA17175027
D008694Methamphetamine[Methamphetamine co-treated with SCH 23390] results in increased expression of CNOT6L mRNA19564919
D008694MethamphetamineMethamphetamine results in increased expression of CNOT6L mRNA19564919
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CNOT6L mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of CNOT6L mRNA23649840
D008774MethylphenidateMethylphenidate results in decreased expression of CNOT6L mRNA22470460
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of CNOT6L mRNA19812364
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of CNOT6L mRNA25729387
D010426Pentosan Sulfuric PolyesterPentosan Sulfuric Polyester results in increased expression of CNOT6L mRNA28973697
D010634PhenobarbitalPhenobarbital affects the expression of CNOT6L mRNA23091169
C006253pirinixic acidpirinixic acid results in increased expression of CNOT6L mRNA17426115|2381119
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of CNOT6L mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of CNOT6L mRNA22079256
C534628SCH 23390[Methamphetamine co-treated with SCH 23390] results in increased expression of CNOT6L mRNA19564919
C534628SCH 23390SCH 23390 results in increased expression of CNOT6L mRNA19564919
D012834SilverSilver results in decreased expression of CNOT6L mRNA27131904
D012969Sodium FluorideSodium Fluoride results in decreased expression of CNOT6L mRNA27862939
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CNOT6L mRNA21570461
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of CNOT6L mRNA25729387
D019772TopotecanTopotecan results in decreased expression of CNOT6L mRNA25729387
C483909torcetrapibtorcetrapib results in increased expression of CNOT6L mRNA23228038
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of CNOT6L mRNA24935251|2627250
C057693troglitazonetroglitazone results in decreased expression of CNOT6L mRNA28973697
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNOT6L mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of CNOT6L mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of CNOT6L mRNA23179753|2800136
D014635Valproic AcidValproic Acid results in increased expression of CNOT6L mRNA26272509
D014750VincristineVincristine results in decreased expression of CNOT6L mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004535poly(A)-specific ribonuclease activity-TAS-  
GO:0005515protein binding-IPI17452450  18377426  21981923  21984185  22977175  26496610  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000289nuclear-transcribed mRNA poly(A) tail shortening-TAS-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0006355regulation of transcription, DNA-templated-IEA-  
GO:0006397mRNA processing-IEA-  
GO:0006977DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest-TAS-  
GO:0008284positive regulation of cell proliferation-IMP21233283  
GO:0010606positive regulation of cytoplasmic mRNA processing body assembly-IMP21233283  
GO:0031047gene silencing by RNA-IEA-  
GO:0061157mRNA destabilization-IEA-  
GO:0090503RNA phosphodiester bond hydrolysis, exonucleolytic-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA21233283  
GO:0005737cytoplasm-IDA21233283  
GO:0005829cytosol-IDA-  
GO:0005829cytosol-TAS-  
GO:0030014CCR4-NOT complex-IDA19558367  
KEGG ID KEGG Term
hsa03018RNA degradation
Reactome ID Reactome Term Evidence
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-3700989Transcriptional Regulation by TP53TAS
R-HSA-429914Deadenylation-dependent mRNA decayTAS
R-HSA-429947Deadenylation of mRNATAS
R-HSA-6791312TP53 Regulates Transcription of Cell Cycle GenesTAS
R-HSA-6804115TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertainTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS
R-HSA-8953854Metabolism of RNATAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal